Literature DB >> 20013323

p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells.

Takayuki Ikezoe1, Jing Yang, Chie Nishioka, Akihito Yokoyama.   

Abstract

We previously showed that AZD1152-HQPA, the inhibitor of Aurora B kinase potently induced growth arrest and apoptosis of various types of human leukemia cells including MV4-11 acute myelogenous leukemia (AML) cells, although the molecular mechanisms by which this class of kinase inhibitors induces apoptosis remain to be fully elucidated. We have recently established the MV4-11 subline, designated as MV4-11 TP53 R248W, which possesses transcriptionally inactive R248W mutation in the TP53 gene. MV4-11 TP53 R248W cells were relatively resistant to AZD1152-HQPA-mediated growth arrest, as measured by MTT and clonogenic assays. AZD1152-HQPA (10-100 nM, 48 h) strikingly induced apoptosis of MV4-11 cells, as assessed by Annexin V binding, loss of mitochondrial outer membrane potential, and activation of caspase cascade, in parallel with up-regulation of p53 and its target molecules Bax and Noxa. Notably, AZD1152-HQPA (10-100 nM, 48 h) induced polyploidy rather than apoptosis in MV4-11 TP53 R248W cells. The polyploid cells were eventually eliminated via apoptosis at later time period (72-120 h) in association with up-regulation of p73. Taken together, p53 plays an important role in AZD1152-HQPA-induced growth arrest and early onset of apoptosis in AML cells. P73 may mediate the late onset of apoptosis to eliminate the polyploid cells caused by the inhibitor of Aurora B kinase.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20013323     DOI: 10.1007/s12185-009-0462-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  29 in total

Review 1.  Dissecting p53-dependent apoptosis.

Authors:  J E Chipuk; D R Green
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

2.  Analysis of Aurora B kinase in non-Hodgkin lymphoma.

Authors:  Takayuki Ikezoe; Tamotsu Takeuchi; Jing Yang; Yoshihiro Adachi; Chie Nishioka; Mutsuo Furihata; H Phillip Koeffler; Akihito Yokoyama
Journal:  Lab Invest       Date:  2009-10-12       Impact factor: 5.662

3.  Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.

Authors:  Andrew A Mortlock; Kevin M Foote; Nicola M Heron; Frédéric H Jung; Georges Pasquet; Jean-Jacques M Lohmann; Nicolas Warin; Fabrice Renaud; Chris De Savi; Nicola J Roberts; Trevor Johnson; Cyril B Dousson; George B Hill; David Perkins; Glenn Hatter; Robert W Wilkinson; Stephen R Wedge; Simon P Heaton; Rajesh Odedra; Nicholas J Keen; Claire Crafter; Elaine Brown; Katherine Thompson; Stephen Brightwell; Liz Khatri; Madeleine C Brady; Sarah Kearney; David McKillop; Steve Rhead; Tony Parry; Stephen Green
Journal:  J Med Chem       Date:  2007-03-21       Impact factor: 7.446

4.  Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways.

Authors:  Takayuki Ikezoe; Yang Yang; Kentaro Bandobashi; Tsuyako Saito; Shigeki Takemoto; Hisanori Machida; Kazuto Togitani; H Phillip Koeffler; Hirokuni Taguchi
Journal:  Mol Cancer Ther       Date:  2005-04       Impact factor: 6.261

5.  AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.

Authors:  Jing Yang; Takayuki Ikezoe; Chie Nishioka; Taizo Tasaka; Ayuko Taniguchi; Yoshio Kuwayama; Naoki Komatsu; Kentaro Bandobashi; Kazuto Togitani; H Phillip Koeffler; Hirokuni Taguchi; Akihito Yokoyama
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

6.  The human MDM-2 oncogene is overexpressed in leukemias.

Authors:  C E Bueso-Ramos; Y Yang; E deLeon; P McCown; S A Stass; M Albitar
Journal:  Blood       Date:  1993-11-01       Impact factor: 22.113

7.  Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.

Authors:  Fernando López-Ríos; Shannon Chuai; Raja Flores; Shigeki Shimizu; Takatoshi Ohno; Kazuhiko Wakahara; Peter B Illei; Sanaa Hussain; Lee Krug; Maureen F Zakowski; Valerie Rusch; Adam B Olshen; Marc Ladanyi
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

8.  Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells.

Authors:  Altaf A Dar; Abbes Belkhiri; Jeffrey Ecsedy; Alexander Zaika; Wael El-Rifai
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

9.  Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.

Authors:  Karl J Aichberger; Matthias Mayerhofer; Karoline V Gleixner; Maria-Theresa Krauth; Alexander Gruze; Winfried F Pickl; Volker Wacheck; Edgar Selzer; Leonhard Müllauer; Hermine Agis; Christian Sillaber; Peter Valent
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

10.  Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia.

Authors:  Kensuke Kojima; Marina Konopleva; Twee Tsao; Hideki Nakakuma; Michael Andreeff
Journal:  Blood       Date:  2008-07-16       Impact factor: 22.113

View more
  12 in total

Review 1.  Aurora kinase inhibitors as anticancer molecules.

Authors:  Hiroshi Katayama; Subrata Sen
Journal:  Biochim Biophys Acta       Date:  2010-09-20

2.  Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes.

Authors:  Marc Payton; Hung-Kam Cheung; Maria Stefania S Ninniri; Christian Marinaccio; William C Wayne; Kelly Hanestad; John D Crispino; Gloria Juan; Angela Coxon
Journal:  Mol Cancer Ther       Date:  2018-09-28       Impact factor: 6.261

3.  High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma.

Authors:  Sarah Wang; Elizabeth E Hwang; Rajarshi Guha; Allison F O'Neill; Nicole Melong; Chansey J Veinotte; Amy Conway Saur; Kellsey Wuerthele; Min Shen; Crystal McKnight; Gabriela Alexe; Madeleine E Lemieux; Amy Wang; Emma Hughes; Xin Xu; Matthew B Boxer; Matthew D Hall; Andrew Kung; Jason N Berman; Mindy I Davis; Kimberly Stegmaier; Brian D Crompton
Journal:  Clin Cancer Res       Date:  2019-04-12       Impact factor: 12.531

4.  Frequency of TP53 Mutations and its Impact on Drug Sensitivity in Acute Myeloid Leukemia?

Authors:  Ankur Shah; Claire Seedhouse
Journal:  Indian J Clin Biochem       Date:  2012-03-24

5.  Aurora B interacts with NIR-p53, leading to p53 phosphorylation in its DNA-binding domain and subsequent functional suppression.

Authors:  Liming Wu; Chi A Ma; Yongge Zhao; Ashish Jain
Journal:  J Biol Chem       Date:  2010-10-19       Impact factor: 5.157

6.  Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.

Authors:  Zijun Y Xu-Monette; Lin Wu; Carlo Visco; Yu Chuan Tai; Alexander Tzankov; Wei-min Liu; Santiago Montes-Moreno; Karen Dybkaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; X Frank Zhao; William W L Choi; Xiaoying Zhao; J Han van Krieken; Qin Huang; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; Fan Zhou; Brad S Kahl; Jane N Winter; Wei Xu; Jianyong Li; Ronald S Go; Yong Li; Miguel A Piris; Michael B Møller; Roberto N Miranda; Lynne V Abruzzo; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2012-09-05       Impact factor: 22.113

7.  Cell cycle control in acute myeloid leukemia.

Authors:  Dominik Schnerch; Jasmin Yalcintepe; Andrea Schmidts; Heiko Becker; Marie Follo; Monika Engelhardt; Ralph Wäsch
Journal:  Am J Cancer Res       Date:  2012-08-20       Impact factor: 6.166

Review 8.  Chromosomal Instability in Acute Myeloid Leukemia.

Authors:  Mateus de Oliveira Lisboa; Paulo Roberto Slud Brofman; Ana Teresa Schmid-Braz; Aline Rangel-Pozzo; Sabine Mai
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

9.  Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target.

Authors:  S A Hartsink-Segers; C M Zwaan; C Exalto; M W J Luijendijk; V S Calvert; E F Petricoin; W E Evans; D Reinhardt; V de Haas; M Hedtjärn; B R Hansen; T Koch; H N Caron; R Pieters; M L Den Boer
Journal:  Leukemia       Date:  2012-09-03       Impact factor: 11.528

10.  Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.

Authors:  Chun-Xiu Yuan; Zhi-Wei Zhou; Yin-Xue Yang; Zhi-Xu He; Xueji Zhang; Dong Wang; Tianxing Yang; Si-Yuan Pan; Xiao-Wu Chen; Shu-Feng Zhou
Journal:  Drug Des Devel Ther       Date:  2015-03-02       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.